NeOnc Technologies Executes Sub-License Agreement, Marking Key Milestone Toward Closing $50 Million Strategic Partnership with Quazar Investment
NeOnc Technologies (NTHI) has executed a crucial Sub-License Agreement with its Abu Dhabi subsidiary NuroCure, marking significant progress toward closing a $50 million strategic partnership with Quazar Investment. The agreement, covering NEO100 and NEO212 in the UAE and MENA region, represents the second of five required conditions for the transaction.
The partnership, priced at $25 per share, allocates 70% for NeOnc common stock acquisition and 30% for MENA region clinical trials and infrastructure. The company must complete three remaining conditions within 120 days, including forming NuroMENA and NuroCure in Abu Dhabi, finalizing offering documents, and approving a two-year business plan.
NeOnc's NEO100 and NEO212 therapeutics are currently in Phase II clinical trials with FDA Fast-Track status, targeting brain and central nervous system cancers.
NeOnc Technologies (NTHI) ha firmato un importante Accordo di Sub-Licenza con la sua filiale di Abu Dhabi, NuroCure, segnando un progresso significativo verso la chiusura di una partnership strategica da 50 milioni di dollari con Quazar Investment. L'accordo, che riguarda NEO100 e NEO212 negli Emirati Arabi Uniti e nella regione MENA, rappresenta la seconda delle cinque condizioni necessarie per la transazione.
La partnership, valutata a 25 dollari per azione, destina il 70% all'acquisizione di azioni ordinarie NeOnc e il 30% ai trial clinici e alle infrastrutture nella regione MENA. L'azienda deve completare le tre condizioni rimanenti entro 120 giorni, tra cui la creazione di NuroMENA e NuroCure ad Abu Dhabi, la finalizzazione dei documenti di offerta e l'approvazione di un piano aziendale biennale.
I farmaci NEO100 e NEO212 di NeOnc sono attualmente in fase II di sperimentazione clinica con lo status Fast-Track della FDA, mirati ai tumori del cervello e del sistema nervoso centrale.
NeOnc Technologies (NTHI) ha firmado un importante Acuerdo de Sub-Licencia con su subsidiaria en Abu Dhabi, NuroCure, marcando un avance significativo hacia el cierre de una asociación estratégica de 50 millones de dólares con Quazar Investment. El acuerdo, que cubre NEO100 y NEO212 en los EAU y la región MENA, representa la segunda de cinco condiciones necesarias para la transacción.
La asociación, valorada en 25 dólares por acción, destina el 70% para la adquisición de acciones ordinarias de NeOnc y el 30% para ensayos clínicos e infraestructura en la región MENA. La empresa debe completar las tres condiciones restantes en 120 días, incluyendo la formación de NuroMENA y NuroCure en Abu Dhabi, la finalización de los documentos de oferta y la aprobación de un plan de negocios a dos años.
Los terapéuticos NEO100 y NEO212 de NeOnc están actualmente en ensayos clínicos de Fase II con estatus Fast-Track de la FDA, dirigidos a cánceres del cerebro y del sistema nervioso central.
NeOnc Technologies (NTHI)는 아부다비 자회사 NuroCure와 중요한 서브 라이선스 계약을 체결하며 Quazar Investment와의 5,000만 달러 전략적 파트너십 체결에 중요한 진전을 이루었습니다. 이 계약은 UAE 및 MENA 지역에서 NEO100과 NEO212를 포함하며, 거래를 위한 다섯 가지 조건 중 두 번째 조건입니다.
이 파트너십은 주당 25달러로 책정되었으며, 70%는 NeOnc 보통주 취득에, 30%는 MENA 지역 임상 시험 및 인프라 구축에 할당됩니다. 회사는 120일 이내에 NuroMENA 및 NuroCure 아부다비 설립, 제안서 최종화, 2년 사업 계획 승인 등 세 가지 남은 조건을 완료해야 합니다.
NeOnc의 NEO100과 NEO212 치료제는 현재 FDA 패스트트랙 지정을 받은 2상 임상시험 중이며, 뇌 및 중추신경계 암을 대상으로 합니다.
NeOnc Technologies (NTHI) a conclu un accord de sous-licence crucial avec sa filiale d'Abu Dhabi, NuroCure, marquant une avancée significative vers la conclusion d'un partenariat stratégique de 50 millions de dollars avec Quazar Investment. L'accord, couvrant NEO100 et NEO212 aux Émirats arabes unis et dans la région MENA, représente la deuxième des cinq conditions requises pour la transaction.
Le partenariat, valorisé à 25 dollars par action, alloue 70 % à l'acquisition d'actions ordinaires NeOnc et 30 % aux essais cliniques et infrastructures dans la région MENA. La société doit remplir les trois conditions restantes dans les 120 jours, incluant la création de NuroMENA et NuroCure à Abu Dhabi, la finalisation des documents d'offre et l'approbation d'un plan d'affaires sur deux ans.
Les thérapeutiques NEO100 et NEO212 de NeOnc sont actuellement en essais cliniques de phase II avec le statut Fast-Track de la FDA, ciblant les cancers du cerveau et du système nerveux central.
NeOnc Technologies (NTHI) hat eine wichtige Unterlizenzvereinbarung mit seiner Tochtergesellschaft in Abu Dhabi, NuroCure, abgeschlossen und damit einen bedeutenden Fortschritt auf dem Weg zum Abschluss einer 50-Millionen-Dollar-Strategiepartnerschaft mit Quazar Investment erzielt. Die Vereinbarung, die NEO100 und NEO212 in den VAE und der MENA-Region umfasst, stellt die zweite von fünf erforderlichen Bedingungen für die Transaktion dar.
Die Partnerschaft ist mit 25 Dollar pro Aktie bewertet und sieht vor, dass 70 % für den Erwerb von NeOnc-Stammaktien und 30 % für klinische Studien und Infrastruktur in der MENA-Region verwendet werden. Das Unternehmen muss die verbleibenden drei Bedingungen innerhalb von 120 Tagen erfüllen, darunter die Gründung von NuroMENA und NuroCure in Abu Dhabi, die Fertigstellung der Angebotsunterlagen und die Genehmigung eines zweijährigen Geschäftsplans.
Die Therapeutika NEO100 und NEO212 von NeOnc befinden sich derzeit in Phase-II-Studien mit FDA-Fast-Track-Status und zielen auf Hirn- und ZNS-Krebserkrankungen ab.
- Strategic $50 million investment commitment at $25 per share, representing significant capital injection
- Inclusion in Russell Microcap Index, potentially increasing institutional investment and market liquidity
- FDA Fast-Track status for both NEO100 and NEO212 therapeutics in Phase II trials
- Patent protection extending to 2038 for proprietary drug candidates
- Geographic expansion into UAE and MENA region through strategic partnership
- Transaction subject to three remaining closing conditions within 120 days
- Partnership based on non-binding term sheet, indicating deal uncertainty
- Significant operational and regulatory requirements for MENA expansion
- Clinical-stage company with no commercialized products yet
Insights
NeOnc's $50M Quazar partnership advances with key licensing milestone, strengthening its financial position and Middle East expansion.
NeOnc Technologies has executed a critical Sub-License Agreement, marking the second of five required conditions to close its
What makes this milestone particularly meaningful is how it positions NeOnc to leverage its recent Russell Microcap Index inclusion alongside this potential capital infusion. The combination could substantially improve the company's liquidity profile and institutional investment appeal - critical factors for clinical-stage biotechs with significant cash burn rates during trial phases.
The remaining three conditions that must be satisfied within 120 days include: formation of NuroMENA and NuroCure in Abu Dhabi, finalization of offering documents, and approval of a comprehensive two-year business plan. These are standard but substantial steps that still present execution risk before the deal closes.
For a small clinical-stage biotech with two lead candidates (NEO100 and NEO212) in Phase II trials with FDA Fast-Track status, securing
CALABASAS, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has achieved a key milestone toward closing its previously announced strategic transaction with Quazar Investment: execution and transfer of a Sub-License Agreement from NeOnc to its Abu Dhabi onshore operating subsidiary, NuroCure. The Sub-License covers the UAE and the wider GCC and MENA region with respect to NEO100 and NEO212, pursuant to NeOnc’s license from USC Stevens Center for Innovation.
On July 8, 2025, NeOnc announced a non-binding term sheet to participate in the contemplated
“We’ve strategically aligned the timing of our Russell Microcap Index inclusion with the Quazar partnership to attract institutional capital, drive passive fund flows, and enhance market liquidity,” said Amir Heshmatpour, Executive Chairman & President of NeOnc Technologies Holdings, Inc.
“It’s a clear stamp of credibility and a core pillar of our broader capital markets strategy. Completing the Sub-License Agreement is a critical milestone that brings us one step closer to unlocking the full potential of our
“It feels like NeOnc is undergoing a major transformation from a clinical-stage biotech to a global brain cancer platform,” added Dr. Ishwar Puri, Senior Vice President, Research & Innovation, University of Southern California.
Under the non-binding term sheet, Quazar intends to lead a capital formation round of up to
To complete the transaction, NeOnc must satisfy the remaining conditions within 120 days, including:
- Legal formation of NuroMENA and NuroCure in Abu Dhabi.
- Finalization of offering documents, including subscription agreements and a shareholder agreement.
- Approval of a comprehensive two-year business plan and budget, outlining operational and clinical milestones.
The closing remains subject to these conditions and the successful completion of the capital formation process.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. For more about NeOnc and its pioneering technology, visit neonc.com.
Important Cautions Regarding Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.
The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
James@haydenir.com
FAQ
What is the value and share price of NTHI's strategic partnership with Quazar Investment?
What are the remaining conditions for NTHI to close the Quazar deal?
What is the current development stage of NTHI's cancer therapeutics?
How long does NTHI's patent protection extend for their drug candidates?
What territories does NTHI's new Sub-License Agreement cover?
